diphtheria, haemophilus, pertussis, tetanus, and polio

Generic Name: diphtheria, haemophilus B, pertussis, polio, tetanus vaccine (dif THEER ee a, hem OFF il us, per TUS is, POE lee oh, TET a nus)
Brand Name: Pentacel

What is diphtheria, haemophilus B, pertussis, polio, tetanus (DTaP-IVP/Hib) vaccine?

Diphtheria, haemophilus influenza type B, pertussis, polio, and tetanus are serious diseases caused by bacteria or virus.

Diphtheria causes a thick coating in the nose, throat, and airways. It can lead to breathing problems, paralysis, heart failure, or death.

Haemophilus B bacteria can infect the lungs or throat, and can also spread to the blood, bones, joints, brain, or spinal cord. It can cause breathing problems or meningitis, and these infections can be fatal.

Pertussis (whooping cough) causes coughing so severe that it interferes with eating, drinking, or breathing. These spells can last for weeks and can lead to pneumonia, seizures (convulsions), brain damage, and death.

Polio affects the central nervous system and spinal cord. It can cause muscle weakness and paralysis. Polio is a life threatening condition because it can paralyze the muscles that help you breathe.

Tetanus (lockjaw) causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw so the victim cannot open the mouth or swallow. Tetanus leads to death in about 1 out of 10 cases.

Diphtheria, haemophilus B, pertussis, and polio are spread from person to person. Tetanus enters the body through a cut or wound.

The DTaP-IVP/Hib vaccine is used to help prevent these diseases in children who are ages 6 weeks through 4 years (before the 5th birthday).

This vaccine works by exposing your child to a small dose of the virus, bacteria or a protein from the bacteria, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.

Like any vaccine, the DTaP-IVP/Hib may not provide protection from disease in every person.

What is the most important information I should know about this vaccine?

Your child should not receive this vaccine if he or she has a neurologic disorder or disease affecting the brain (or if this was a reaction to a previous vaccine).

Slideshow: 2013 Drug News Round-Up: Top 20 Stories

What should I discuss with my healthcare provider before receiving this vaccine?

Your child should not receive this vaccine if he or she has ever had a life-threatening allergic reaction to any vaccine containing diphtheria, haemophilus, pertussis, polio, or tetanus. Your child also should not receive this vaccine if he or she has a neurologic disorder or disease affecting the brain (or if this was a reaction to a previous vaccine).

Your child may not be able to receive this vaccine if he or she has ever received a similar vaccine that caused any of the following:

  • a very high fever (over 104 degrees), excessive crying for 3 hours or longer, fainting or going into shock (within 48 hours after receiving a vaccine containing pertussis);

  • an allergy to neomycin, streptomycin or polymyxin B, or yeast;

  • a seizure (within 3 days after receiving a vaccine containing pertussis); or

  • Guillain-Barré syndrome (within 6 weeks after receiving a vaccine containing tetanus).

If your child has any of these other conditions, this vaccine may need to be postponed or not given at all:

  • a history of seizures or premature birth; or

  • a weak immune system caused by disease, bone marrow transplant, or by using certain medicines or receiving cancer treatments.

Your child can still receive a vaccine if he or she has a minor cold. In the case of a more severe illness with a fever or any type of infection, wait until the child gets better before receiving this vaccine.

How is this vaccine given?

This vaccine is injected into a muscle. You will receive this injection in a doctor's office or clinic setting.

This vaccine is given in a series of shots. The first shot is usually given when the child is 2 months old. The booster shots are then given at 4 months, 6 months, and 15 to 18 months of age. Your child's individual booster schedule may be different from these guidelines. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.

Your doctor may recommend treating fever and pain with an aspirin free pain reliever such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil, and others) when the shot is given and for the next 24 hours. Follow the label directions or your doctor's instructions about how much of this medicine to give your child.

It is especially important to prevent fever from occurring in a child who has a seizure disorder such as epilepsy.

What happens if I miss a dose?

Contact your doctor if you will miss a booster dose or if you get behind schedule. The next dose should be given as soon as possible. There is no need to start over.

Be sure your child receives all recommended doses of this vaccine. Your child may not be fully protected if he or she does not receive the full series.

What happens if I overdose?

An overdose of this vaccine is unlikely to occur.

What should I avoid before or after receiving this vaccine?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

This vaccine side effects

Your child should not receive a booster vaccine if he or she had a life-threatening allergic reaction after the first shot. Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shot caused any side effects.

Becoming infected with diphtheria, haemophilus B, pertussis, polio, or tetanus is much more dangerous to your child's health than receiving this vaccine. However, like any medicine, this vaccine can cause side effects but the risk of serious side effects is extremely low.

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if the child has any of these side effects:

  • irritability, crying for an hour or longer;

  • very high fever; or

  • extreme drowsiness, fainting.

Common side effects may include:

  • low fever, mild fussiness; or

  • redness, pain, tenderness, or swelling where the shot was given.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report vaccine side effects to the US Department of Health and Human Services at 1 800 822 7967.

See also: Side effects (in more detail)

Diphtheria, haemophilus, pertussis, tetanus, and polio dosing information

Usual Pediatric Dose for Haemophilus influenzae Prophylaxis:

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Poliomyelitis Prophylaxis:

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Diphtheria Prophylaxis:

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Pertussis Prophylaxis:

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

Usual Pediatric Dose for Tetanus Prophylaxis:

Diphtheria/haemophilus/pertussis/tetanus/polio (Pentacel) vaccine is approved for administration as a 4 dose series at 2, 4 and 6, and 15 18 months of age. The first dose may be given as early as 6 weeks of age. Four doses of Pentacel vaccine constitute a primary immunization course against pertussis. Three doses of Pentacel vaccine constitute a primary immunization course against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis; the fourth dose constitutes a booster vaccination against diphtheria, tetanus, H influenzae type B invasive disease, and poliomyelitis

Children who have completed a four dose series with Pentacel vaccine should receive a fifth dose of DTaP vaccine at 4 to 6 years of age. Because the pertussis antigens in DAPTACEL vaccine are the same as those in Pentacel vaccine (although with different amounts of detoxified PT and FHA), these children should receive DAPTACEL vaccine as their fifth dose of DTaP. However, data are not available to evaluate the safety of DAPTACEL vaccine following four previous doses of Pentacel vaccine.

Children previously vaccinated with one or more doses of DAPTACEL vaccine: Pentacel vaccine may be used to complete the first 4 doses of the DTaP series in infants and children who have received 1 or more doses of DAPTACEL vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of IPV: Pentacel vaccine may be used to complete the 4 dose IPV series in infants and children who have received 1 or more doses of another licensed IPV vaccine and are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated.

Children previously vaccinated with one or more doses of Haemophilus B conjugate vaccine: Pentacel vaccine may be used to complete the vaccination series in infants and children previously vaccinated with one or more doses of a Haemophilus B conjugate vaccine (either separately administered or as part of another combination vaccine), who are also scheduled to receive the other antigens of Pentacel vaccine. However, the safety and efficacy of Pentacel vaccine in such infants have not been evaluated. If different brands of Haemophilus B conjugate vaccines are administered to complete the series, three primary immunizing doses are needed, followed by a booster dose.

What other drugs will affect diphtheria, haemophilus B, pertussis, polio, and tetanus vaccine?

Before your child receives this vaccine, tell the doctor if your child has recently received any drugs or treatments that can weaken the immune system. If your child is using any of these medications, he or she may not be able to receive the vaccine, or may need to wait until the other treatments are finished.

Where can I get more information?

  • Your doctor or pharmacist can provide more information about this vaccine. Additional information is available from your local health department or the Centers for Disease Control and Prevention.
  • Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
  • Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 2.01. Revision Date: 2013-11-14, 10:00:21 PM.

Hide
(web2)